A groundbreaking treatment method, altering the patient’s immune cells, has decreased the risk of disease progression by 74 percent in individuals suffering from rare blood cancer.
The treatment, known commercially as Carvykti and scientifically as Ciltacabtagene autoleucel, was experimented with in a clinical trial that involved 419 multiple myeloma patients. These patients were unresponsive to the existing primary drug, lenalidomide, a chemotherapy medication.
“Lenalidomide has established itself as a staple in myeloma care. However, as its usage grows, so does the number of patients who become resistant to the treatment,” noted oncologist Oreofe Odejide. According to Odejide, Ciltacabtagene autoleucel “provides incredibly effective results compared to current options for patients” and “can be safely introduced earlier in the treatment process.”
Multiple myeloma, a disease that affects a kind of white blood cell known as plasma cells, can induce a chain of damage to the bones, kidneys, and immune health. According to the Cleveland Clinic, it affects seven out of every 100,000 people yearly, with around 100,000 cases reported in the United States alone. While there is no known cure, disease progression can often be halted for an extended period.
In this new clinical trial, half of the patients were randomly allocated Ciltacabtagene autoleucel, while the rest received a combination of drugs currently considered standard care, including chemotherapy and steroids.
After 16 months of median follow-up, the research showed that Ciltacabtagene autoleucel reduced the risk of disease progression by 74 percent compared to the standard treatments.
Ciltacabtagene autoleucel is a form of chimeric antigen receptor (CAR) T-cell therapy, an innovative treatment approach. In this process, a patient’s T cells, responsible for combating diseases, are removed and genetically modified in a lab to possess specific proteins or receptors. Once re-introduced into the body, these receptors help identify and destroy cancer cells.
It was noted, however, that nearly all patients from both groups encountered severe or potentially life-threatening side effects, including infections and low blood cell counts. Furthermore, 75 percent of patients on Ciltacabtagene autoleucel developed Cytokine release syndrome, a condition in which the immune system goes into hyperdrive, affecting multiple organs and potentially causing death.
The researchers intend to continue monitoring the study participants to evaluate long-term effects and impacts on the quality of life. This clinical trial was financed by Janssen Research & Development and Legend Biotech USA.
, has been shown to reduce the risk of disease progression in multiple myeloma patients by 74%. This groundbreaking CAR T-cell therapy alters the patient's own immune cells to more effectively combat cancer.){kind=link}